Cabo VerdeTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.11–0.21) 31 (22–41)
Mortality (HIV+TB only) 0.026 (0.022–0.031) 5.1 (4.2–6)
Prevalence  (includes HIV+TB) 1.2 (0.64–2) 236 (124–384)
Incidence  (includes HIV+TB) 0.71 (0.63–0.8) 138 (122–156)
Incidence (HIV+TB only) 0.066 (0.055–0.078) 13 (11–15)
         
Case detection, all forms (%) 39 (34–44)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
4 (1–7) 5 (1–8)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 172   9
Pulmonary, clinically diagnosed 41   0
Extrapulmonary 52   0
       
Total new and relapse 274    
Previously treated, excluding relapses 18    
Total cases notified 292    
Among 265 new cases:
11 (4%) cases aged under 15 years; male:female ratio: 3.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB     4
Laboratory-confirmed RR-/MDR-TB cases     5
Patients started on MDR-TB treatment ***     5
TB/HIV 2014 Number (%)
TB patients with known HIV status 290 (99)
HIV-positive TB patients 27 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 24 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 25 (93)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 214  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 302
Previously treated cases, excluding relapse, registered in 2013 (42) 12
HIV-positive TB cases, all types, registered in 2013 (83) 24
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 3.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-25 Data: www.who.int/tb/data